IXHL Stock Overview
A clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Incannex Healthcare Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.98 |
| 52 Week High | US$12.68 |
| 52 Week Low | US$1.50 |
| Beta | 2.21 |
| 11 Month Change | -12.38% |
| 3 Month Change | 0.52% |
| 1 Year Change | -53.95% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.67% |
Recent News & Updates
Shareholder Returns
| IXHL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.1% | 1.6% | 2.2% |
| 1Y | -53.9% | 9.9% | 31.6% |
Return vs Industry: IXHL underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: IXHL underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| IXHL volatility | |
|---|---|
| IXHL Average Weekly Movement | 13.3% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IXHL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IXHL's weekly volatility has decreased from 24% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 9 | Joel Latham | www.incannex.com |
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn’s disease.
Incannex Healthcare Inc. Fundamentals Summary
| IXHL fundamental statistics | |
|---|---|
| Market cap | US$34.94m |
| Earnings (TTM) | -US$23.15m |
| Revenue (TTM) | US$86.00k |
406.3x
P/S Ratio-1.5x
P/E RatioIs IXHL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IXHL income statement (TTM) | |
|---|---|
| Revenue | US$86.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$86.00k |
| Other Expenses | US$23.24m |
| Earnings | -US$23.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.31 |
| Gross Margin | 100.00% |
| Net Profit Margin | -26,922.09% |
| Debt/Equity Ratio | 0% |
How did IXHL perform over the long term?
See historical performance and comparison